Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
MAH Marketing Approval Priority Review and Approval Innovative Drug Generic Drug Biological Product Diabetes Rare Disease Drug Registration New DrugMonthly Report: New Drug Approvals in China | August 2022 In August 2022, China NMPA approved 13 new drugs, including 9 chemical drugs and 4 biological products. Among them, MSD's HPV 9-valent vaccine got approval to expand the target group from females 16-26 years of age to 9-45 years of age.
Sep 09, 2022
China to Carry out National Insulin Procurement China will pilot a nationwide insulin procurement which may refer to the previous pilot insulin procurement scheme in Wuhan. It means the price of insulin products will be significantly reduced, and the market share of relevant pharmaceutical companies in China will be affected.
Mar 08, 2021
Chinese Market Becomes More Intense for Antidiabetic Drugs China's fourth round of national centralized drug procurement has begun, according to the Jinfu Chen, deputy head of the National Healthcare Security Administration in Beijing on Jan. 29, 2021. This time five new diabetes medications are included in the procurement list. They are empagliflozin, canagliflozin, repaglinide, nateglinide, and gliclazide.
Mar 08, 2021
- China CDE Q&A | Drug Registration Applications & Clinical Trials
- How to Sell OTC Drugs to China via Cross-Border E-Commerce
- China's First Homegrown COVID-19 Pill, Azvudine, is Priced at 270 Yuan Per Bottle
- Monthly Report: New Drug Approvals in China | July 2022
- Monthly Report: New Drug Approvals in China | August 2022